(+/-)-2-phenyl-succinamic acid | 712-57-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+/-)-2-phenyl-succinamic acid
• 英文别名: 2-phenyl-succinamic acid；(+/-)-2-Phenyl-succinamidsaeure；α-Phenyl-aethan-α.β-dicarbonsaeure-β-amid；Phenylbernstein-β-amid-α-saeure；2-Phenyl-succinamidsaeure；3-carbamoyl-2-phenylpropionic acid；4-Amino-4-oxo-2-phenylbutanoic acid
• CAS: 712-57-2
• 化学式: C₁₀H₁₁NO₃
• 分子量: 193.202
• InChiKey: RBFBHLMFDNKPIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+/-)-2-phenyl-succinamic acid 在 次溴酸钾 作用下， 生成 3-氨基-2-苯基丙酸
  参考文献：
  名称：

  A New Synthesis of dl-Tropic Acid

  摘要：

  DOI：

  10.1021/ja01202a510
• 作为产物：
  描述：

  2-phenylsuccinic anhydride 在 乙醚 、 氨 作用下， 生成 (+/-)-2-phenyl-succinamic acid
  参考文献：
  名称：

  Anschuetz; Walter, Justus Liebigs Annalen der Chemie, 1908, vol. 361, p. 77

  摘要：

  DOI：

文献信息

• Felbamate derived compounds
  申请人：——

  公开号：US20020156070A1

  公开（公告）日：2002-10-24

  The present invention relates to novel felbamate derivatives and their use to treat neurological diseases such as epilepsy and to treat tissue damage resulting form ischemic events. The felbamate derivatives are modified to prevent the formation of metabolites that are believed responsible for the toxicity associated with felbamate therapy.

  本发明涉及新型费巴酯衍生物及其用于治疗癫痫等神经系统疾病和治疗因缺血事件导致的组织损伤的用途。费巴酯衍生物经过改良，以防止形成被认为与费巴酯疗法相关的毒性代谢物。
• Substituted felbamate derived compounds
  申请人：——

  公开号：US20040023986A1

  公开（公告）日：2004-02-05

  The present invention relates to novel felbamate derivatives and their use to threat neurological diseases such as epilepsy and neuropathic pain, and to treat tissue damage resulting form ischemic events. The felbamate derivatives are modified to prevent the formation of metabolites that are believed responsible for the toxicity associated with felbamate therapy.

  本发明涉及新的费拉巴麦衍生物及其用于治疗神经系统疾病，如癫痫和神经病性疼痛，并用于治疗缺血事件导致的组织损伤。费拉巴麦衍生物经过改良，以防止形成被认为与费拉巴麦治疗相关的毒性代谢产物。
• ANTIVIRAL AGENTS
  申请人：Kumar V. Dange

  公开号：US20070287699A1

  公开（公告）日：2007-12-13

  Compounds are provided having utility for the treatment of viral infections, particularly HCV.

  提供了化合物，可用于治疗病毒感染，尤其是HCV。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods
  申请人：BUSCHMANN Heinrich Helmut

  公开号：US20110224172A1

  公开（公告）日：2011-09-15

  Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene compounds and processes for their production, the use thereof for producing pharmaceutical compositions, pharmaceutical compositions containing these compounds and methods of treatment using these compounds.

  替代1-氧杂-2,8-二氮杂螺[4,5]癸-2-烯类化合物及其制备方法，用于制备药物组合物，含有这些化合物的药物组合物和使用这些化合物的治疗方法。